Pentaxim Injection

Pentaxim Injection is a pentavalent combination vaccine designed for active immunization against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive infections caused by Haemophilus influenzae type b (Hib). This vaccine is indicated for primary vaccination in infants from two months of age and for booster vaccination during the second year of life.

The vaccine is formulated as a powder and suspension for injection, requiring reconstitution prior to administration. It is administered via the intramuscular route, preferably in the anterolateral side of the thigh for infants and the deltoid area for children.

Key Features : 

Provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive Haemophilus influenzae type b infections, including meningitis and septicaemia.
Approved for primary vaccination in infants from two months of age and for booster vaccination one year after primary vaccination during the second year of life.
Requires cold-chain storage, maintaining a temperature between 2°C and 8°C, and must not be frozen.
Administered intramuscularly, with recommended injection sites being the anterolateral thigh for infants and the deltoid area for children.
First licensed in Sweden in 1997 and approved by regulatory bodies such as the Ministry of Food and Drug Safety (MFDS) in South Korea and registered in the Russian Federation.